Technology & Devices

Roche Enters Drug Discovery Collaboration with Vividion Focused on Novel E3 Ligases

SAN DIEGO, May 19, 2020 /PRNewswire/ — Vividion Therapeutics, a biotechnology company discovering and developing highly selective small molecule medicines that drug traditionally inaccessible targets, today announced that it has entered into an exclusive worldwide option and license agreement with Roche (SIX: RO, ROG;OTCQX: RHHBY) to leverage its proteomics screening …

Read More »

FDA Informs Public About Possible Accuracy Concerns with Abbott ID NOW Point-of-Care Test to Diagnose COVID-19

Today, the U.S. Food and Drug Administration is alerting the public to early data that suggest potential inaccurate results from using the Abbott ID NOW point-of-care test to diagnose COVID-19. Specifically, the test may return false negative results. “We are still evaluating the information about inaccurate results and are in …

Read More »

Bayer and ArcherDX Announce Global Collaboration to Develop NGS-based Companion Diagnostic for Vitrakvi

BOULDER, Colo. & BERLIN–(BUSINESS WIRE)–Bayer and ArcherDX, Inc. today announced a global collaboration for the development and commercialization of a next-generation sequencing (NGS)-based companion diagnostic (CDx) for Vitrakvi® (larotrectinib). The primary objective of the collaboration is to broaden patient access to comprehensive genomic testing inclusive of neurotrophic receptor tyrosine kinase 1 …

Read More »

Abbott Receives FDA Emergency Use Authorization for COVID-19 Molecular Test on New Alinity m System

ABBOTT PARK, Ill., May 12, 2020 /PRNewswire/ — Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the company’s molecular test for the novel coronavirus (COVID-19) for use on its new Alinity™ m molecular laboratory instrument. Abbott is in …

Read More »

Skyhawk and Merck Expand Collaboration Agreement with to Discover and Develop Novel Small Molecules that Modulate RNA Splicing

WALTHAM, Mass., May 12, 2020 /PRNewswire/ — Skyhawk Therapeutics, Inc. (“Skyhawk”) today announced that it has expanded its strategic collaboration with Merck, known as MSD outside the United States and Canada, to discover, develop and commercialize small molecules that modulate RNA splicing. Skyhawk’s proprietary SkySTARTM technology platform will be employed …

Read More »

Specifica Transfers Antibody Discovery Platform to Bayer

SANTA FE, N.M., May 12, 2020 /PRNewswire/ — Specifica, a leading provider of antibody discovery technologies, today announced the transfer of a suite of Specifica’s Generation 3 antibody libraries to Bayer under an agreement that will enable the development of antibody-based therapeutics. Antibody Libraries are the sources from which therapeutic …

Read More »

Novartis and Dyno Therapeutics Enter Ocular Collaboration to Develop Improved Gene Therapies with AAV Vectors based on AI Technology

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dyno Therapeutics, a biotechnology company applying artificial intelligence (AI) to gene therapy, today announced a collaboration with Novartis to develop improved Adeno-Associated Virus (AAV) vectors for research, development, and commercialization of gene therapies for ocular diseases. The partnership will allow the parties to utilize Dyno’s CapsidMap™ artificial intelligence …

Read More »

Research from University of Washington Demonstrates High Performance of Abbott’s SARS-CoV-2 Antibody Blood Test

ABBOTT PARK, Ill., May 8, 2020 /PRNewswire/ — Abbott (NYSE: ABT) announced today new research, published in the Journal of Clinical Microbiology, which found that its SARS-CoV-2 IgG lab-based serology blood test had 99.9% specificity and 100% sensitivity for detecting the IgG antibody in patients 17 days or more after …

Read More »

FDA Approves FoundationOne®CDx as the Companion Diagnostic for Tabrecta, a MET Inhibitor for Patients with Metastatic NSCLC with METex14

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc. today announced that FoundationOne®CDx has been approved by the U.S. Food and Drug Administration (FDA) for use as the companion diagnostic (CDx) to aid in identifying patients with non-small cell lung cancer (NSCLC) for whom treatment with Tabrecta™ (capmatinib) may be appropriate. Tabrecta is the …

Read More »

AVROBIO Collaborates with Saladax Biomedical on New High-Speed Diagnostic Assay Used with Busulfan Conditioning

CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced a new development and commercialization agreement with Saladax Biomedical, Inc. (Saladax), a leading diagnostics provider focused on developing blood tests for personalized dosing, to …

Read More »